Globus Medical Inc (GMED) Stock Price & Analysis
Globus Medical Inc (GMED) rose 0.22% to USD 78.29 as of September 8, 2026 at 05:47 UTC, according to Nexqual real-time market data.
GMED last closed at USD 78.29; the session ranged USD 77.07–78.69 on volume of 1,123,624 shares. Market capitalization is —, with a 52-week range of USD 54.15–101.4 (NYQ). Source: Nexqual, September 8, 2026 at 05:47 UTC.
Key Statistics (as of September 8, 2026 at 05:47 UTC)
| Price | USD 78.29 |
|---|---|
| Change | ▲ 0.22% (up) |
| Previous Close | USD 78.29 |
| Open | USD 78.29 |
| Day Range | USD 77.07 – 78.69 |
| 52-Week Range | USD 54.15 – 101.4 |
| Volume | 1,123,624 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (GMED)
Nexqual's technical model rates GMED "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.01 (neutral) |
| vs SMA50 | Below (USD 80.98) |
| MACD | -0.59 (negative) |
From Globus Medical Inc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- We, and our third-party manufacturers, are subject to the quality system regulations of the FDA, state regulations (such as the regulations promulgated by the California Department of Health Services), and regulations promulgated by foreign regulatory bodies (such as in the European Union (the "EU")).
- Food and Drug Administration Regulation Our products meet the FDA's definition of medical devices (per Section 201(h)(1) of the Food, Drug, and Cosmetic Act) and human tissue products (under 21 CFR Parts 1270 and 1271 or Public Health Service Act Section 361), each subject to varying regulation(s) by the FDA and other federal, state, local and foreign regulatory bodies.
- Certain HCT/Ps are regulated solely under Section 361 of the Public Health Service Act and are referred to as "Section 361 HCT/Ps," while other HCT/Ps are subject to the FDA's regulatory requirements for medical devices or biologics in addition to the regulatory requirements under 21 CFR Parts 1270 and 1271.
- Our surgeon education and training program integrates surgical training with professional development and enables us to introduce surgeons to our comprehensive portfolio and patented approaches to spine surgery.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WEX | WEX Inc. | USD 193.91 | ▲ 0.55% |
| APPN | Appian Corporation | USD 38.37 | ▼ 3.81% |
| IDXX | IDEXX Laboratories, Inc. | USD 535.38 | ▼ 0.67% |
| PODD | Insulet Corporation | USD 147.48 | ▼ 0.45% |
| PEN | Penumbra, Inc. | USD 322.17 | ▼ 0.2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:47 UTC. This page is informational and not investment advice.